Abstract: The present invention provides a powder-assembled composite micro-nano fiber and a method for preparing the powder-assembled composite micro-nano fiber. The method includes the following steps: (1) preparing two-dimensional cellulose from a cellulose-raw-material; (2) dispersing the two-dimensional cellulose and a powder material in a solvent to form a mixed suspension; and (3) performing freeze drying on the mixed suspension to obtain the powder-assembled composite micro-nano fiber, wherein a temperature difference between two ends in a vertical direction of the mixed suspension is controlled to be 10-100° C. in a freezing process of the freeze drying. In the present invention, a new non-destructive processing path from primary particles to macro applications is constructed, and rich material platforms and infinite possibilities are provided for basic studies and technical applications.

Abstract: A pet food that comprises a soybean protein isolate, a fermented soybean meal or a mixture thereof wherein a content of ?-conglycinin is 5 mass % to 10 mass % in terms of dry matter, a content of a plant-based protein other than a plant-based protein derived from the soybean protein isolate and the fermented soybean meal is 11.0 mass % or less in terms of dry matter, and digestibility of a protein contained in the pet food is 88% or more.

Abstract: A composition and method of preparing a pea protein hydrolysate includes obtaining a pea protein composition, adding a fungal protease to the pea protein composition, and hydrolyzing the pea protein composition to a degree of hydrolysis of about 4% or greater to obtain a pea protein hydrolysate. In an example, the degree of hydrolysis can range from about 4% to about 25% at a pH ranging from about 5 to about 7.5 and at a temperature ranging from about 30° C. to about 60° C. The resulting pea protein hydrolysate has a solubility of at least 30% at pH 3.4, a viscosity of at least 65 cPs at pH 3.4, a dispersibility of at least 115 seconds at about neutral pH, and a suspendability of at least 1.5 TSI Global at pH 3.4.

Abstract: Kits and methods of using the kits for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding are disclosed. The sample analysis kits employ nucleic acid encoding and/or nucleic acid recording of a molecular interaction and/or reaction, such as recognition events (e.g., between an antigen and an antibody, between a modified terminal amino acid residue, or between a small molecule or peptide therapeutic and a target, etc.). Additional barcoding reagents, such as those for cycle-specific barcoding (e.g., “clocking”), compartment barcoding, combinatorial barcoding, spatial barcoding, or any combination thereof, may be included in the kits. The sample may comprise macromolecules, including peptides, polypeptides, and proteins, and the recording may generate molecular interaction and/or reaction information, and/or polypeptide sequence information.

Abstract: The present invention relates to an injectable pharmaceutical composition containing keratin for preventing hair loss or stimulating hair growth, wherein the composition is excellent in hair follicle generating and hair growth stimulating effects, and thus can be favorably used as a preventive and therapeutic agent for hair loss or a stimulating agent for hair growth.

Abstract: The invention relates to a dispenser of a sealant for hemostasis comprising a container configured to receive a fibrinogen solution and an activation compartment being situated downstream of the container and comprising a functionalized support to which a coagulation factor, preferably thrombin, is immobilized, such that upon dispensing the fibrinogen solution it passes through the activation compartment, thereby generating and dispensing polymerizing fibrin as a sealant. The invention further relates to a support, exchangeable tip and a kit for the dispenser as well as to methods and uses of the dispenser or components thereof for dispensing a sealant to a desired site.

Abstract: The subject invention pertains to methods for producing novel occidiofungin analogues lacking xylose (OF-?xyl analogue). OF-?xyl analogues can contain aldehyde, amine, triazole, or hydrazones. The aldehyde, amine, triazole or hydrazone containing analogues of OF-?xyl can be further modified by substitution with additional functional groups. Various OF-?xyl analogues described herein have reduced inflammation and toxicity and superior pharmacological properties compared to the natural occidiofungins. Accordingly, certain embodiments of the invention provide methods of treating or preventing fungal infections by administering to the subjects in need thereof the OF-?xyl analogues described herein.

Abstract: Tetrazine non-canonical amino acids, methods for genetic encoding proteins and polypeptides using the tetrazine amino acids, proteins and polypeptides comprising the tetrazine amino acids, and compositions comprising the proteins and polypeptides having at least one post-translational modification thereof comprising in vivo reaction with the incorporated tetrazine amino acid and a second molecule.

Abstract: The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

Abstract: Provided is a flexible polyurethane foam having high hardness required for weight reduction of members and having low stress relaxation. A flexible polyurethane foam comprises a structural protein fiber having a length of 0.1 mm to 5 mm.

Abstract: The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

Abstract: The present invention relates to a field of biotechnology. It discloses a novel amino acid sequence of recombinant human bone morphogenetic protein-2 (rhBMP-2) and encoded nucleotide sequences thereof, and a method for preparing rhBMP-2. In the present invention, by further optimizing the nucleotide sequence of rhBMP-2, novel amino acid sequence of rhBMP-2 that can express good ectopic induced osteogenic activity and has good renaturation and purification effect is screened out. The engineered bacteria constructed by the present invention can induce the production of recombinant rhBMP-2 protein with an expression level of about 55%, and the produced target protein is more easily denatured and purified than the existing recombinant rhBMP-2, with better denaturation and purification effect and higher osteoinductive activity.

Abstract: Food-grade pulse protein concentrates prepared from various pulses and flours derived therefrom are provided. Also provided are method of making the concentrates and beverages and foodstuffs that include the concentrates. The pulse protein concentrates are characterized by a high protein content, high digestibility, and complete essential amino acid profile.

Abstract: The invention comprises several embodiments of a multi-step method for processing hard tissues, including bone, teeth, tooth enamel and dentin, mollusk shells, crustacean shells, deep sea sponge, coral, radiolarians, diatoms, antler bone, and other naturally occurring mineralized biocomposites, and soft tissues, including connective tissue, cartilage, tendon, ligament, vertebral discs, pathological mineralized soft tissues and other soft tissues, including at least processing a portion of tissue by one or more of contacting, immersing, adding and mixing a portion of tissue with a first solution, obtaining a first material, derived from processing the portion of tissue with the first solution, processing the first material using one or more alkali metal and ammonium salts of citrate, acetate, phosphate, sulfate, tartarate and chloride, and obtaining a resulting material, derived from processing the first material with the one or more salts.

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

Abstract: The present disclosure relates to a foodstuff composition, in particular a spreadable food composition, more in particular an olive oil-based functional spread fat composed by olive oil fortified with a functional ingredient—the olive pomace active ingredient. This functional ingredient is a mixture of bioactive compounds, in particular hydroxytyrosol, tyrosol, sterols, tocopherols, triterpenes, coenzyme Q10, K, Mg and Ca, among others, obtained from olive pomace by mechanical pressing.

Abstract: Techniques and apparatus for performing target compound detection processes are described. In one embodiment, for example, an apparatus may include at least one memory, and logic coupled to the at least one memory. The logic may be configured to implement a targeted compound detection process, for example, by receiving raw data from analysis of a sample via an analytical device, generating cumulative data from the raw data, receiving compound specification information associated with the sample, and determining quantified compound information via performing targeted compound detection based on the cumulative data and the compound specification information to determine. Other embodiments are described.

Abstract: The present invention relates to serine protease variants, having improved properties compared to the parent protease, in particular variants of a serine protease derived from a strain of Meripilus giganteus belonging to the S53 family. The varinats according to the invention have in particular increased stability, e.g., increased thermo-stability, increased specific activity, and/or increased expression levels, compared to the parent protease. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: Compounds, compositions, and methods are provided for covalently linking an antibody or an antibody fragment to a cargo molecule, such as a therapeutic or a diagnostic agent, using a combination of enzymatic glycan remodeling and click chemistry. The method allows a cargo molecule to be selectively and efficiently attached post-translationally to an antibody or an antibody fragment. Also provided are antibody drug conjugates, methods of making, and uses thereof.

Abstract: Reagents and methods for extracting and stabilizing metabolites at room temperature and methods in which metabolites and one or more of proteins, lipids and nucleic acids are extracted from a single sample in a unified workflow.

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

Abstract: Disclosed herein are low density particles comprising polymerized fibrin that are micrometer or nanometer sized in diameter. The particles can further include at least one therapeutic agent. The particles may be used to treat wounds, by administration directly or systemically to the site of the wound. Exemplary wounds that may be treated with the fibrin particles include a trauma wound, a surgical wound, a burn wound, or an ulcer wound. Also disclosed herein are methods for preparing the particles using a shearing process.

Abstract: The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.

Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of toxic proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.

Abstract: Disclosed herein are methods and platforms using Receptor Compartmentalized Partnered Replication (CPR), in which the partner gene is a receptor, signal transduction pathway, or metabolic pathway that leads to the production of an effector molecule for the receptor or signal transduction pathway. The signal transduction pathway or receptor is coupled to the production of a thermostable polymerase. Emulsification of libraries of organisms with primers that can amplify the partner gene led to the selective amplification of those partner genes that were best able to produce the thermostable polymerase during thermal cycling of the emulsion.

Abstract: A defibrated material manufacturing device is configured to defibrate a feedstock of clumps of shreds containing fiber into defibrated material. The defibrated material manufacturing device has a removal device, a metering device, storage device, and a defibrator. The removal device is configured to remove at least a part of foreign matter contained in the feedstock. The metering device is configured to measure the feedstock that has passed the removal device. The storage device is configured to store a measured feedstock measured by the metering device. The defibrator is configured to defibrate the measured feedstock supplied from the storage device into the defibrated material.

Abstract: The invention relates to a glycoprotein-toxic pay-load molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composi-tion. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tu-mour cells.

Abstract: The present invention provides reagents for instrumentation quality control and methods of use thereof. In particular, sets of peptides or other molecules are provided for evaluating the performance of instruments with mass spectrometry (MS) and/or liquid chromatography (LC) functionalities.

Abstract: The present invention relates to a method for producing an active form of a long-acting insulin analogue derivative, in which the amino acid at position 22 of the insulin B-chain is substituted from arginine (Arg) to lysine (Lys), so that the insulin analogue can be converted to an active form without cleavage of the B-chain even when it is reacted with clostripain. In a conventional method of converting pro-insulin to an active form by use of trypsin, an albumin binding domain is cleaved, making it difficult to convert the long-acting insulin analogue derivative to an active form. The production method according to the present invention overcomes this difficulty, and thus it can be effectively used for the production of a long-acting therapeutic agent for treatment of diabetes.

Abstract: Food-grade pulse protein concentrates prepared from various pulses and flours derived therefrom are provided. Also provided are method of making the concentrates and beverages and foodstuffs that include the concentrates. The pulse protein concentrates are characterized by a high protein content, high digestibility, and complete essential amino acid profile.

Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.

Abstract: The present invention is directed to a polymer of Formula (IV): wherein A, X, Q, Y, Z, m1; m2, m3, k1; and k2 are as described herein and wherein the monomer units of the polymer are the same or different. The present invention also relates to a monomer of Formula (III), wherein R?, X1, Y1, Z1, m4, m5, and m6 are as described herein, and a polymeric network comprising two or more monomers of Formula (III). The present invention also relates to a hydrogel comprising any of the polymers and monomers described herein, a capsule comprising the hydrogel, and a method of delivering a therapeutic agent to a subject using the capsule.

Abstract: An antibody-drug conjugate (ADC) has a structure represented by Formula (I): a pharmaceutically acceptable salt thereof wherein Ab is an antibody without glycans (i.e., the protein portion an antibody); G1 and G2 are glycan moieties, which may be the same or different; Cn1 and Cn2 are conjugation moieties, which may be the same or different; L1 and L2 are linker moieties, which may be the same or different; D1 and D2; are drug units which may be the same or different; and x and y are independently an integer from 0 to 8, provided that x+y?0.

Abstract: The present disclosure provides materials and methods for cell-free expression of epitopes for immunotherapy applications. In particular, the present disclosure provides materials and methods for expressing concatenated epitopes using a cell-free protein synthesis platform for high throughput, large scale, and unbiased epitope screening and the generation of multi-epitope vaccines.

Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.

Abstract: Gene sequences are tailored for protein expression by measuring ribosome dynamics, training a statistical model of the relationship between DNA sequence and translation speed; and using this model to design an optimal DNA sequence encoding a given protein.

Abstract: The present invention describes methods for quantifying and analyzing cell migration and drug screening. Such methods include a gel (or a hydrogel) comprising a polymer, and cells that forms an oxygen gradient within the gel by controlling the balance of the diffusion of oxygen through the top of the gel and by the consumption of oxygen uptake by the cells. The migration of the cells is determined while the cells are grown in the gel of the present invention.

Abstract: An ultrasound-assisted simulated digestion method of a milk protein active peptide and an application thereof in health foods, pertaining to the technical field of intensive processing of dairy products and preparation of health foods. The method firstly employs ultrasonic pretreatment of casein and ?-lactoglobulin, followed by enzymatic hydrolysis with a protease to prepare casein and ?-lactoglobulin polypeptide, and traces the activity of the polypeptide by simulating gastrointestinal digestion, and then simulates absorption by intestinal epithelial cells with Caco-2 cells, to characterize a highly active milk protein polypeptide digested by the gastrointestinal tract and absorbed by the Caco-2 cells simulating absorption by the inner wall of the small intestine. The method has identified five such highly active milk protein polypeptides.

Abstract: The present invention relates to polypeptide variants of porcine trypsin, to nucleic acid molecules encoding these variants, and to host cells comprising such nucleic acid molecules. It also relates to the use of these variants in methods for producing insulin. The invention further relates to the use of these variants as medicaments, as food ingredients, or as feed ingredients and to the use of these variants within a process of manufacturing a food ingredient or a feed ingredient.

Abstract: The present invention relates to a preparation method for various novel fucosyl oligosaccharides and a use thereof. More specifically, the present invention allows a preparation of various novel fucosyl oligosaccharides through an enzymatic reaction with ?-1,2-fucosyltransferase using a GDP-L-fucose donor and various glucose acceptors and an establishment of probiotic characteristics thereof, and thus has an effect of providing uses as materials for medicines, food, cosmetic products, and the like.

Abstract: Disclosed is a method of measuring protein kinase activity, including a) attaching GMBS (N-[?-maleimidobutyryloxy]sulfosuccinimide ester) to a base plate, b) attaching a substrate that reacts with a protein kinase to the base plate having GMBS attached thereto, thus manufacturing a kit for measuring protein kinase activity, c) introducing, to the kit, a mixture of a sample to be analyzed and a buffer including triton X-100, and d) probing phosphorylation of the substrate caused by the protein kinase contained in the sample, thereby measuring the activity of the protein kinase.

Abstract: A method of preparing an anti-oxidation polypeptide having an amino acid sequence of SEQ ID NO:1 includes enzymatic hydrolysis of black shark skins, which serve as the raw material, with alkali protease, separation, purification, freezing, and drying to obtain the anti-oxidation polypeptide. Enzymatic hydrolysis conditions include 7.0-9.0 pH value, 40-50° C. temperature, 4.0-6.0 h enzymatic hydrolysis time, 2.0-4.0% primer concentration, and 9.0-10.0 wt % of enzymes.

Abstract: A mixed-mode chromatography method for the determination of phosphorylated sugars in a sample is provided. The mixed-mode chromatography method includes obtaining a sample comprising at least one phosphorylated sugar. The sample is introduced onto a chromatography system. The chromatography system includes a column having a stationary phase material contained inside the column. The stationary phase material has a surface comprising a hydrophobic surface group and at least one ionizable modifier. The sample with a mobile phase eluent is flowed through the column, where the at least one phosphorylated sugar is substantially resolved and retained within seven minutes. The mobile phase eluent includes water with an additive and acetonitrile with the additive. The mobile phase eluent has a pH less than 6. The at least one phosphorylated sugar is detected using a detector.

Abstract: The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.

Abstract: The presently disclosed subject matter provides antigen-binding proteins that specifically bind to Preferentially expressed antigen of melanoma (PRAME), including humanized, chimeric and fully human antibodies against PRAME, antibody fragments (e.g., scFv, Fab and F(ab)2), chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a PRAME peptide/HLA class I molecule complex. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of PRAME associated diseases, including for example, breast cancer, ovarian cancer, melanoma, lung cancer, gastrointestinal cancer, brain tumor, head and neck cancer, renal cancer, myeloma, neuroblastoma, mantle cell lymphoma, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML), Non-Hodgkin lymphoma (NHL), and Chronic lymphocytic leukemia (CLL).

Abstract: A drug delivery system and methods of using such for delivering a peglyated therapeutic agent to brain. The drug delivery system may comprise an antibody, which binds polyethylene glycol (PEG), wherein the antibody is embedded in a hydrogel, which may comprises one or more biodegradable polymers, up to 60% of which contain inter-chain or intra-chain covalent crosslinks. The amount of the antibody in the drug delivery system can be about 1-2 ?g per ?l of the hydrogel.

Abstract: A heparin structure with increased anticoagulant activity and method of making the same are disclosed. A heparin sample is provided and treated with a heparan sulfate sulfotransferase in an enzymatic reaction to add sulfuryl groups from a sulfuryl group source to the heparin sample, resulting in a heparin structure having above about 8% more 3-O-sulfo groups relative to wild-type bovine intestinal heparin. The added sulfuryl groups modify the heparin structure and increase the sample's binding to antithrombin III and its anticoagulant activity to be more similar and a viable alternative to porcine intestinal heparin. The modified heparin exhibits an anti-FXa activity and an anti-FIIa activity greater than about 180 U/mg, and a ratio of the anti-FXa activity to the anti-FIIa activity of about 0.9 to about 1.1, consistent with U.S. Pharmacopeia (USP) heparin activity specifications.

Abstract: Described are compositions comprising ?-galactosidase A enzymes with unique carbohydrate profiles, as well as methods for manufacturing and purifying such enzymes. Also described methods of treating, preventing, and/or ameliorating Fabry Disease by administering such enzymes to a subject in need thereof. Also described are compositions comprising migalastat in combination with such ?-galactosidase A enzymes.

Abstract: Field of application: The invention relates to organic and bioorganic combinatorial chemistry, namely, to new combinatorial libraries of derivatives oligopeptides and supramolecular structures based on them, which when used without separation into individual components possess powerful antiviral properties. The essence of the invention: The invention is based on the task of synthesizing combinatorial derivatives of oligopeptides with antiviral properties and with a new mechanism of action, the use of which will significantly increase the effectiveness of treatment and reduce the treatment time for viral diseases such as influenza, herpes virus infections.